H. Lundbeck A/s

COPENHAGEN, Denmark, January 18, 2011 - Lundbeck welcomes the news that patients in England and Wales with moderate or severe Alzheimer's, within specific conditions, will qualify for treatment with Ebixa(R) under the Final Appraisal Determination (FAD) from the National Institute for Health and Clinical Excellence (NICE)[1].